Rocket Pharmaceuticals, Inc. (RCKTW)
NCM
$0.00+0.00 (+1900.00%)Quote refreshed
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Market Cap
—
P/E (TTM)
—
EPS
—
Div Yield
—
52W Range
$0.00–$0.01
Beta
—
Company overview
No company overview is available for Rocket Pharmaceuticals, Inc. yet.
Peers in industry
Rocket Pharmaceuticals, Inc. has no peer companies in this window.
Recent press releases
April 2026
6 months agoDEF 14A
ROCKET PHARMACEUTICALS, INC. — DEF 14A Filing
RCKTWROCKET PHARMACEUTICALS, INC.
# 🧾 What This Document Is This is Rocket Pharmaceuticals' **definitive proxy statement (DEF 14A)**. It's an official invitation and information packet for shareholders ahead of the **2026 Annual Meeting on May 20, 2026**. The purpose is to let shareholders vote on key company decisions. 👉 *Why
Read summaryView on SEC EDGAR
SEC filings
All filings →1 recent filing shown in the timeline above. View all SEC filings →
Insider trades
All insider trades →Rocket Pharmaceuticals, Inc. has no reported insider trades in the last 90 days.
Institutional holders
All holders →As of 2025-12-31 · prior 2025-09-30
MAVERICK CAPITAL LTD$8.8M
2,513,110 sh-70.3%
CITIGROUP INC$18.4M
5,246,349 sh+50224.7%
VANGUARD GROUP INC$30.0M
8,544,423 sh+24.0%
1,586,076 sh-59.4%
1,784,921 sh-50.0%
BlackRock, Inc.$27.8M
7,906,071 sh+11.1%
RTW INVESTMENTS, LP$62.1M
17,687,772 sh0.0%
955,000 sh● NEW
People at Rocket Pharmaceuticals, Inc.
All people →No officers or directors have been indexed for Rocket Pharmaceuticals, Inc..
Quarterly financials
Full financials →Revenue trend
03/25
—
NI -$61.3M
06/25
—
NI -$68.9M
09/25
—
NI -$50.3M
RevenueNI = Net Income
EPS trend (diluted)
Latest: $-0.45
Prior: $-0.62
Revenue sparkline